Loading patent…
AssigneesWarsaw Orthopedic, Inc., Medtronic, Inc.
InventorsWilliam F. McKay, Christopher M. Hobot, Danielle Biggs, Katara Shaw, John Myers Zanella, Vanja M. King, Stephen Mark Cox, Kathy L. Remsen
Estimating the term…
Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
An implantable drug depot for reducing, preventing or treating pain, inflammation, and/or tissue transplant rejection in a patient in need of such treatment, the implantable drug depot comprising fluocinolone or a pharmaceutically acceptable salt thereof in an amount from about 0.5 wt. % to about 25 wt. % of the drug depot, and at least one biodegradable polymer, wherein the drug depot is capable of releasing fluocinolone or pharmaceutically acceptable salt thereof over a period of at least three days.
An implantable drug depot for reducing, preventing or treating inflammation, pain, and/or tissue transplant rejection in a patient in need of such treatment, the implantable drug depot comprising fluocinolone acetonide in an amount of from about 0.5 wt. % to about 25 wt. % of the drug depot, and at least one polymer, wherein the at least one polymer comprises one or more of poly(lactide-co-glycolide), D-lactide, D,L-lactide, L-lactide, D,L-lactide-caprolactone, or D,L-lactide-glycolide-ε-caprolactone.
A method for reducing, preventing or treating inflammation, pain, and/or tissue transplant rejection, wherein said method comprises implanting a drug depot at a target tissue site in a patient in need of such treatment to reduce, prevent or treat tissue transplant rejection, wherein said drug depot comprises fluocinolone or a pharmaceutically acceptable salt thereof in an amount from about 0.05 wt. % to about 25 wt. % of the drug depot, and at least one biodegradable polymer.
Dependencies are inferred from the claim text.